Our study showed that in breast cancer patients, GOLPH3 overexpression was associated with resistance to neoadjuvant chemotherapy, especially to the most frequently used regimen of anthracycline+taxane+cyclophosphamide, although these results were based on data from a small number of patients. This evidence concerns the gene GOLPH3 and breast cancer.